Related Experiment Video
Updated: Jul 18, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Can't kick that oncogene habit
1Cancer Research Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco Comprehensive Cancer Center, 2340 Sutter Street, San Francisco, California 94143, USA. gevan@cc.ucsf.edu
Abstract:
One of the most exciting developments in recent cancer treatment has been the move away from crude cytotoxic agents toward drugs that inhibit specific targets in specific cellular pathways. One assumption of this strategy is that maintenance of human cancers is dependent upon a limited cadre of therapeutically tractable oncogenic lesions. In this issue of Cancer Cell, an intriguing paper from Sharma et al. endorses this approach by showing that evolution appears to be working for us. They show that an innate asymmetry in the dynamics of intracellular signaling biases pathway inhibition in favor of cell death. This bias may significantly potentiate targeted cancer therapies.
Insights
Targeted cancer therapies are enhanced by intracellular signaling dynamics. This innate asymmetry favors cell death, improving treatment efficacy against specific oncogenic pathways.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Modern cancer treatment shifts from cytotoxic agents to targeted therapies inhibiting specific oncogenic pathways.
- This strategy assumes cancer maintenance relies on a limited set of targetable genetic alterations.
- Sharma et al. investigate the role of intracellular signaling in cancer treatment efficacy.
Discussion:
- The study reveals an inherent asymmetry in intracellular signaling dynamics.
- This asymmetry naturally biases pathway inhibition towards inducing cancer cell death.
- This finding supports the efficacy of targeted cancer therapies.
Key Insights:
- Evolutionary dynamics favor targeted cancer therapies by creating signaling asymmetries.
- Intracellular signaling bias potentiates the effectiveness of drugs targeting specific oncogenic pathways.
- This mechanism offers a new perspective on overcoming cancer resistance.
Outlook:
- Further research can explore exploiting this signaling bias for novel therapeutic strategies.
- Understanding these dynamics may lead to more personalized and effective cancer treatments.
- This work highlights the potential of integrating evolutionary principles into cancer drug development.
Related Concept Videos
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Induced Pluripotent Stem Cells
Somatic cells are...
Cancer Prevention
Some...

